Acelyrin, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

19 Mar 2025

SLRN

10-K: Acelyrin's 10-K Filing Reveals Merger Plans, Strategic Shift to Lonigutamab, and Financial Details

Acelyrin's annual report highlights a planned merger with Alumis, a strategic focus on lonigutamab for TED, and a detailed financial overview for 2024.

28 Mar 2024

SLRN

Acelyrin, INC

10-K: Acelyrin, Inc. Details Common Stock and Corporate Governance in SEC Filing

Acelyrin, Inc.'s 10-K filing outlines the details of its common stock, voting rights, dividend policies, and anti-takeover provisions, as well as key dates and financial metrics.